Parexel International Corp. (PRXL) Given New $64.00 Price Target at Jefferies Group
Parexel International Corp. (NASDAQ:PRXL) had its price objective cut by Jefferies Group from $67.00 to $64.00 in a research report released on Wednesday morning. They currently have a hold rating on the stock.
Other equities analysts also recently issued reports about the company. Credit Suisse Group AG restated a buy rating on shares of Parexel International Corp. in a report on Tuesday, September 27th. First Analysis downgraded Parexel International Corp. from an overweight rating to an equal weight rating and set a $62.00 price objective on the stock. in a report on Thursday, November 17th. Zacks Investment Research upgraded Parexel International Corp. from a sell rating to a hold rating in a report on Tuesday, November 1st. Evercore ISI restated a buy rating and issued a $70.00 price objective (down from $79.00) on shares of Parexel International Corp. in a report on Saturday, October 29th. Finally, Deutsche Bank AG cut their price objective on Parexel International Corp. from $71.00 to $65.00 and set a hold rating on the stock in a report on Friday, October 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $66.70.
Shares of Parexel International Corp. (NASDAQ:PRXL) remained flat at $58.16 during trading on Wednesday. 1,083,520 shares of the company were exchanged. The company has a 50-day moving average price of $62.05 and a 200-day moving average price of $64.14. The company has a market cap of $3.10 billion, a P/E ratio of 18.64 and a beta of 0.91. Parexel International Corp. has a 12-month low of $51.16 and a 12-month high of $71.13.
Parexel International Corp. (NASDAQ:PRXL) last issued its quarterly earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by $0.10. Parexel International Corp. had a return on equity of 30.71% and a net margin of 7.09%. The business earned $500.90 million during the quarter, compared to analyst estimates of $525.15 million. During the same period in the previous year, the business posted $0.70 earnings per share. The firm’s quarterly revenue was down 2.2% on a year-over-year basis. On average, equities research analysts anticipate that Parexel International Corp. will post $3.75 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRXL. Quantbot Technologies LP raised its position in Parexel International Corp. by 644.3% in the second quarter. Quantbot Technologies LP now owns 1,630 shares of the company’s stock worth $102,000 after buying an additional 1,411 shares in the last quarter. MSI Financial Services Inc increased its stake in shares of Parexel International Corp. by 17.4% in the third quarter. MSI Financial Services Inc now owns 1,690 shares of the company’s stock valued at $117,000 after buying an additional 250 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Parexel International Corp. by 13.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,806 shares of the company’s stock valued at $125,000 after buying an additional 213 shares during the last quarter. Robecosam AG increased its stake in shares of Parexel International Corp. by 40.1% in the second quarter. Robecosam AG now owns 2,200 shares of the company’s stock valued at $132,000 after buying an additional 630 shares during the last quarter. Finally, Paradigm Asset Management Co. LLC increased its stake in shares of Parexel International Corp. by 683.3% in the second quarter. Paradigm Asset Management Co. LLC now owns 2,350 shares of the company’s stock valued at $148,000 after buying an additional 2,050 shares during the last quarter. Institutional investors and hedge funds own 96.13% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Parexel International Corp. (PRXL) Given New $64.00 Price Target at Jefferies Group” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of US & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/24/parexel-international-corp-prxl-given-new-64-00-price-target-at-jefferies-group.html.
About Parexel International Corp.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.
Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.